P16 Methylation Leads to Paclitaxel Resistance of Advanced Non-Small Cell Lung Cancer

Paclitaxel-based chemotherapy is widely used as the first-line treatment for non-small cell lung cancer (NSCLC). However, only 20%-40% of patients have shown sensitivity to paclitaxel. This study aimed to investigate whether P16 methylation could be used to predict paclitaxel chemosensitivity of NSC...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhaojun, Lin, Hongmei, Gan, Ying, Cui, Chenghua, Zhang, Baozhen, Gu, Liankun, Zhou, Jing, Zhu, Guangying, Deng, Dajun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547999/
https://www.ncbi.nlm.nih.gov/pubmed/31205528
http://dx.doi.org/10.7150/jca.26482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547999/
https://www.ncbi.nlm.nih.gov/pubmed/31205528
http://dx.doi.org/10.7150/jca.26482

Ejemplares similares